Multi-Organ Transplant AlloSure Monitoring Market : Global Industry Analysis and Opportunity Assessment, 2036

How big is Multi-Organ Transplant AlloSure Monitoring Market in 2026?

USD 514.5 million in 2026 and USD 1218.0 million by 2036 at a 9.0% CAGR.

Sales of multi-organ transplant AlloSure monitoring are projected to expand at 9.0% CAGR from 2026 to 2036, supported by recurring molecular surveillance. Industry value is forecast to rise from USD 514.5 million in 2026 to USD 1218.0 million by 2036 and remains linked to longer recipient follow-up. Clinical adoption depends on repeatable blood collection and organ-specific interpretation across established transplant diagnostics pathways and specialist care teams. Natera reported twenty-one Prospera presentations across kidney and heart or lung plus multi-organ transplantation in June 2026. The evidence base supports broader routine surveillance but each program must define escalation rules and confirm reimbursement coverage. Programs also need specimen tracking that protects collection timing and links unexpected results with urgent specialist review.

Kidney programs provide the largest operating base and heart or lung pathways require different clinical thresholds. United States reimbursement policy creates a separate commercial test through medical necessity criteria and covered testing intervals. CMS issued its solid-organ allograft rejection response in July 2026 and linked coverage to defined clinical uses. Laboratories must connect molecular testing results with treatment decisions instead of reporting isolated biomarker values. Point-of-care molecular systems remain adjacent workflow benchmarks rather than direct substitutes for centralized transplant interpretation and specialist clinical support. Investment becomes defensible once transplant teams measure avoided biopsies and faster intervention without weakening clinical oversight. Cross-border laboratory services face additional delays that can reduce rapid molecular detection value for distant transplant centers.

Summary of the Multi-Organ Transplant AlloSure Monitoring Market

Market Signal	Commercial Impact
Demand and Growth Drivers	Post-transplant programs gain value from surveillance that identifies graft injury before routine chemistry produces a complete clinical explanation. The market is projected to expand, supported by expanding transplant activity and structured rejection monitoring. Repeatable blood collection reduces operational burden for recipients who otherwise depend on invasive procedures during uncertain clinical episodes. Coverage policies strengthen adoption when each test answers a defined medical question and changes a documented treatment decision. Laboratory turnaround and specialist review determine whether molecular signals reach clinicians early enough to influence care escalation.
Product and Segment View	The product framework separates biomarker method from organ pathway and clinical purpose across one post-transplant monitoring program. Donor-derived cell-free DNA monitoring is expected to hold 32.6% share in 2026 driven by its direct measure of graft-derived injury signals. Kidney transplantation is projected to represent 44.4% share in 2026 underpinned by procedure volume and established surveillance pathways. Acute rejection monitoring is forecast to account for 37.9% share in 2026 owing to the consequence of delayed treatment decisions. Transplant centers are estimated to capture 30.8% share in 2026 supported by specialist ownership of interpretation and intervention.
Geography and Growth Outlook	Country growth reflects transplant capacity and payment rules together with local laboratory access and specialist training. Japan is projected to advance at 9.9% CAGR through 2036, linked to concentrated specialist programs and substantial kidney waiting-list pressure. The United Kingdom is forecast to record 9.6% CAGR over the forecast period, underpinned by coordinated national transplant pathways and centralized evidence review. The USA is estimated to post 9.0% CAGR from 2026 to 2036, attributable to large procedure volumes and defined coverage processes. Germany and South Korea require local validation strategies that address reimbursement review and service support across multiple hospital systems.
Competitive Landscape	Competition separates centralized clinical services from laboratory kits and enabling platforms used inside transplant monitoring workflows. CareDx and Natera provide multi-organ dd-cfDNA services with organ-specific reporting and established United States commercial pathways. Eurofins Transplant Genomics and Verici Dx concentrate on kidney monitoring through different biomarker and reporting approaches. Devyser Diagnostics and Insight Molecular Diagnostics support decentralization through assay workflows designed for qualified clinical laboratories. Thermo Fisher Scientific and Bio-Rad Laboratories contribute distribution or analytical platforms without replacing clinical interpretation ownership.
Analyst Perspective	The commercial test is whether molecular surveillance changes a defined transplant decision without adding avoidable testing or interpretation delays. Hospitals must compare organ coverage and clinical support separately because a broad assay menu does not guarantee usable interpretation. Laboratories need documented pre-analytical controls since weak sample handling can undermine a clinically sophisticated analytical workflow. Procurement decisions should assign responsibility for payer documentation and urgent consultation before routine testing volumes expand. - Anurag Sharma, Principal Analyst at Future Market Insights

Source: FMI's proprietary forecasting model and primary research

How is the multi-organ transplant allosure monitoring market segmented?

The multi-organ transplant AlloSure monitoring industry is segmented by test type, organ type, application, end user, and region.

The segmentation framework separates measurement technology from the organ receiving clinical surveillance and the decision supported by each result. Test type covers dd-cfDNA monitoring and complementary molecular approaches used to characterize graft injury or immune activity. Organ analysis follows kidney and heart programs alongside lung and liver pathways that require different baseline interpretation. Application categories distinguish acute rejection monitoring from routine surveillance and immunosuppression management or graft dysfunction assessment. End-user analysis separates transplant centers from hospitals and diagnostic laboratories or specialty clinics with different ownership of clinical action. Regional analysis considers transplant capacity and payment rules together with laboratory access across national health systems.

What supports demand for Donor-derived Cell-free DNA Monitoring within the Test Type category?

Transplant clinicians need a repeatable signal that complements organ function tests during uncertain post-transplant episodes. dd-cfDNA measures graft-derived injury through a blood sample and supports longitudinal review across liquid biopsy methods. CareDx reported in June 2026 that AlloSure studies covered kidney and heart or lung monitoring across more than 110 United States transplant centers. Clinical programs gain value from the biomarker once result thresholds connect with biopsy decisions and immunosuppression review.

• By test type, donor-derived cell-free DNA monitoring is expected to hold 32.6% share in 2026 attributable to its direct connection with graft injury assessment. The method supports serial testing without repeating invasive tissue collection during every uncertain clinical episode across long-term recipient follow-up. Commercial differentiation depends on organ-specific validation and clear interpretation rather than a generic cell-free DNA measurement.
• Transplant laboratories adopt dd-cfDNA workflows through centralized services or validated local assays based on staffing and sample logistics. Automated molecular platforms can reduce manual variability but laboratories retain responsibility for quality controls and report review. Service response during elevated results remains essential since delayed consultation can weaken the value of rapid analytical turnaround.

How does Kidney Transplantation shape demand within the Organ Type category?

Kidney recipients create sustained surveillance demand through large patient cohorts and long follow-up periods across transplant programs. Routine surveillance must balance early injury detection with testing discipline across nephrology and transplant teams. Recurrent testing affects payer review and laboratory capacity so programs need defined patient groups and escalation protocols. Organ-specific thresholds also require consistent sample timing and result interpretation across affiliated clinics that share recipient management responsibilities.

• Based on organ type, kidney transplantation is projected to represent 44.4% share in 2026 underpinned by established post-transplant clinics and repeated graft assessment. The January 2026 UNOS release recorded 27,573 United States kidney transplants during 2025 across established clinical programs. More than 90,000 people remained on the kidney waiting list and explain surveillance capacity without independently proving the approved share.
• Kidney programs can begin adoption through defined patient groups such as early surveillance or unexplained creatinine changes. Clinical diagnostics systems need interfaces that preserve collection timing and treatment context beside each molecular result. Hospitals face friction from coverage documentation and inconsistent ordering protocols across nephrology teams and outside laboratories.

Why is Acute Rejection Monitoring central to the Application category?

Acute rejection creates a time-sensitive decision that requires evidence beyond routine laboratory trends and clinical symptoms. Molecular monitoring can support biopsy selection or treatment assessment through protocols that define clinical ownership and follow-up timing. Programs therefore need rapid consultation and organ-specific thresholds that distinguish surveillance signals from findings requiring immediate intervention. Clinical value declines if reports present a risk score without explaining limitations or expected escalation actions.

• Acute rejection monitoring is forecast to account for 37.8% share in 2026 owing to the consequence of delayed recognition and treatment. Molecular testing can support biopsy selection or treatment assessment within a documented pathway that defines clinical ownership and follow-up timing. The share position reflects a specific clinical decision rather than universal replacement of histology and conventional laboratory measures.
• Transplant specialists favor monitoring programs that provide rapid consultation during unexpected molecular elevations and conflicting conventional results. Natera and Eledon announced in June 2026 that Prospera was selected exclusively for a planned Phase 3 kidney transplant trial. Clinical NGS analysis supports structured review while the trial demonstrates adoption through defined treatment evaluation rather than unrestricted routine testing.

How are Transplant Centers positioned within the End User category?

Transplant centers coordinate blood collection and organ-specific interpretation with treatment changes across multidisciplinary clinical teams. CareDx's current interpretation guidance provides organ-specific report walkthroughs and trend views for kidney or heart and lung results. The guidance also directs clinicians toward the Care Team for questions about reports or result interpretation. Transplant centers therefore control whether molecular evidence becomes a timely decision or remains an isolated laboratory result.

• In 2026, transplant centers are estimated to capture 30.8% share, supported by specialist ownership of surveillance protocols and escalation decisions. Centralized governance allows nephrologists and surgeons to align ordering cadence with biopsy and immunosuppression pathways. The end-user position depends on clinical coordination rather than the physical location of every analytical instrument.
• Large centers can support recurring testing volumes but smaller programs may rely on referral laboratories and remote interpretation services. Genomic workflows require validated collection procedures and secure transfer of organ-specific clinical context across participating organizations. Service contracts should define sample recollection and urgent result escalation plus payer documentation responsibilities across every participating clinical location.

What are the drivers, restraints, and opportunities in the multi-organ transplant allosure monitoring market?

Rising transplant activity supports structured molecular surveillance while reimbursement rules and interpretation demands limit indiscriminate testing.

• Driver: Larger post-transplant populations increase demand for repeatable injury assessment between routine visits and clinically indicated biopsies.
• Restraint: Coverage criteria and variable ordering protocols restrict adoption without documented medical necessity and organ-specific interpretation.
• Opportunity: Integrated molecular and clinical reporting can support earlier escalation through one governed surveillance pathway.

Expanding transplant activity creates a durable monitoring need across recipients who require years of follow-up. HRSA reported in January 2026 that the United States supported nearly 48,600 solid organ transplants during 2025. The larger active recipient base supports recurring tests but clinical teams must define cadence and treatment consequences. Diagnostic providers gain durable demand through protocols that improve longitudinal visibility without encouraging redundant testing.

Coverage discipline is one of the growth restraint because molecular testing can become repetitive without a documented clinical question. CMS published a future-effective billing article in July 2026 that permits one molecular service per patient indication and encounter. The article takes effect on August 30, 2026 and separates molecular testing from biopsy billing except under rare documented circumstances. Laboratories need documentation and appeal workflows that prevent reimbursement burden from shifting to transplant clinics.

Integrated reporting creates an opportunity to combine dd-cfDNA with organ function and antibody or transcriptomic evidence. For instance, CareDx's AlloSure Kidney documentation describes AlloSure Plus as an automated risk tool that combines dd-cfDNA with traditional clinical measures. NGS quality controls provide a broader framework for controlling analytical variation across sequencing workflows and repeated patient measurements. Clinical systems can display trends beside treatment events and biopsy findings through one patient record. Commercial value increases through fewer disconnected reports and clearer accountability for timely follow-up actions across transplant clinical teams.

Which country CAGRs are profiled in the multi-organ transplant allosure monitoring market?

Country	CAGR
USA	9.0%
UK	9.6%
Germany	7.9%
Japan	9.9%
South Korea	7.6%

How do country-level CAGRs compare in the multi-organ transplant allosure monitoring market?

The country comparison shows a relatively narrow spread in projected growth rates across the market. Japan and the UK are closely aligned and create an upper group with only a small gap between them. The USA sits slightly below this group and remains separated by a modest margin. Germany and South Korea form a closely spaced lower pair with very little difference in their forecast expansion rates. The total gap between the first and last country is 2.3 percentage points which highlights a fairly concentrated growth outlook. These differences reflect variations in transplant monitoring adoption, reimbursement support and clinical testing practices across healthcare systems.

• Japan shows a notable position within the comparison as transplant centers continue to expand the use of non-invasive graft monitoring tools in routine patient follow-up.
• The UK remains close to Japan in CAGR terms but follows a different adoption path through structured clinical evaluation and healthcare system integration.
• The USA occupies a measured middle position as AlloSure monitoring benefits from an established transplant ecosystem and broad physician familiarity.
• Germany remains closely aligned with South Korea yet follows a distinct market path where adoption is often shaped by clinical evidence requirements and reimbursement considerations.
• South Korea holds a comparable position to Germany as growing use of precision diagnostics supports transplant monitoring while adoption continues to depend on hospital-level implementation.

Comparable CAGRs do not create identical market conditions across countries. Differences in reimbursement policies, transplant center capabilities, clinical workflow integration and regulatory requirements can influence adoption timing even when growth rates are closely aligned. Market opportunities therefore depend on local implementation conditions as much as forecast expansion. The full report provides country-level CAGR analysis across North America, Latin America, Europe, East Asia, South Asia, Oceania and the Middle East and Africa.

Country-wise Analysis

• United States transplant programs combine Medicare coverage rules with centralized molecular laboratories and large specialist referral networks. The multi-organ transplant AlloSure monitoring market in the USA is projected to expand at 9.0% CAGR over the forecast period, supported by established coverage pathways. In January 2026, the Centers for Medicare & Medicaid Services updated its United States billing article and listed covered assays for kidney or heart and lung indications. CareDx and Natera provide centralized multi-organ services while Eurofins supports kidney-focused monitoring through laboratory-developed testing. Medical-necessity criteria and payer-specific documentation create material friction across transplant programs with different referral patterns and payer mixes. Providers need local billing support and clearly assigned escalation routes before expanding recurring surveillance across affiliated transplant hospitals.
• United Kingdom transplant services use national registers and specialist centers that coordinate referrals across publicly funded clinical pathways. The multi-organ transplant AlloSure monitoring demand in the UK is forecast to rise at 9.6% CAGR through 2036, linked to coordinated clinical oversight. Centralized governance can support consistent ordering protocols but commissioning decisions remain local to participating services. NHS Blood and Transplant reported a waiting list of 8,237 people in March 2026 based on its January 29 2026 count and identified fifteen pilot assessment centers. Centralized foreign services and European assay kits require separate commissioning or validation routes across the United Kingdom. Commercial plans need health-economic evidence and dependable sample logistics across regional providers serving nationally coordinated transplant programs.
• Germany combines Eurotransplant allocation with a defined transplant center network and nationally regulated diagnostic services. The multi-organ transplant AlloSure monitoring market in Germany is estimated to advance at 7.9% CAGR by 2036, underpinned by specialist capacity and European assay availability. Official January 2026 data from Deutsche Stiftung Organtransplantation recorded forty-three German centers and 3,256 transplanted organs during 2025. Thermo Fisher Scientific distributes the kidney-focused One Lambda Devyser Accept cfDNA workflow for qualified laboratories. Reimbursement review and local integration can delay routine use beyond research programs across separate hospital systems. Entrants need German-language interpretation and responsive field service before transplant laboratories expand recurring clinical testing.
• Japanese transplant monitoring develops within highly specialized programs that emphasize graft preservation across long recipient follow-up. The multi-organ transplant AlloSure monitoring adoption in Japan is projected to advance at 9.9% CAGR from 2026 to 2036, shaped by concentrated expertise and long-term recipient management. National candidate registration supports coordinated specialist oversight but imported services face local authorization and sample logistics. The Japan Organ Transplant Network recorded 14,983 registered kidney candidates across Japan on June 30 2026. Limited deceased-donor activity restricts procedure scale and international transport can weaken clinically useful turnaround for foreign providers. Market entry should prioritize local clinical partnerships and structured training for dependable interpretation under Japanese regulatory requirements.
• South Korean adoption depends on tertiary hospitals that combine transplant surgery with advanced molecular laboratory capability. Hospital purchasing requires local authorization and Korean-language interpretation alongside reimbursement review for routine clinical use. The multi-organ transplant AlloSure monitoring market in South Korea is anticipated to record 7.6% CAGR between 2026 and 2036, sustained by specialist infrastructure and evolving technology review. An April 2025 Ministry of Health and Welfare notice proposed revised immediate-entry procedures for qualifying medical devices across South Korea. The proposed route can shorten selected technology reviews but it does not remove clinical evaluation or payment requirements. Commercial entry requires a domestic clinical partner and defined post-sale support for laboratory implementation and clinician education.

Who are the notable companies in the multi-organ transplant allosure monitoring market?

CareDx, Natera, Eurofins Transplant Genomics, Thermo Fisher Scientific, Devyser Diagnostics, Insight Molecular Diagnostics, Bio-Rad Laboratories, and Verici Dx

Competition separates complete clinical monitoring services from organ-specific assays and analytical platforms used inside transplant workflows. Current CareDx and Natera product documentation identifies dd-cfDNA pathways for kidney and heart or lung monitoring with organ-specific reporting. Their services depend on validated sequencing reagents and laboratory controls without transferring interpretation ownership to component suppliers. Eurofins Transplant Genomics and Verici Dx focus on kidney rejection through gene-expression or transcriptomic testing. Thermo Fisher Scientific distributes the One Lambda Devyser Accept cfDNA workflow for qualified laboratories in selected markets. Devyser Diagnostics and Insight Molecular Diagnostics pursue decentralized kidney assays through sequencing or digital PCR. Bio-Rad documented a strategic investment supporting an Oncocyte transplant-testing partnership for laboratory customers in February 2025.

• CareDx and Natera combine organ-specific dd-cfDNA testing with interpretation support across centralized United States workflows.
• Eurofins Transplant Genomics and Verici Dx provide laboratory-developed rejection assessments through distinct molecular signatures.
• Thermo Fisher Scientific and Devyser Diagnostics support assay implementation while Insight Molecular Diagnostics and Bio-Rad Laboratories provide digital PCR routes.

Competitive Benchmarking: Multi-Organ Transplant AlloSure Monitoring Market

Company	Multi-Organ Monitoring	dd-cfDNA Workflow	Interpretation Support	Geographic Reach
CareDx	High	High	High	United States
Natera	High	High	High	United States
Eurofins Transplant Genomics	Medium	High	High	United States
Thermo Fisher Scientific	Medium	High	Medium	Europe and selected markets
Devyser Diagnostics	Medium	High	Medium	Europe and selected markets
Insight Molecular Diagnostics	Medium	Medium	Medium	United States research markets
Bio-Rad Laboratories	Low	Medium	Low	United States partnership
Verici Dx	Medium	Low	High	United States

Multi-Organ Monitoring is High for dedicated testing across at least three solid organs and Medium for one or two organs. A Low rating identifies an enabling platform without a current organ-specific clinical monitoring test for transplant recipients. dd-cfDNA Workflow is High for a commercial transplant-specific assay and Medium for a validated enabling instrument or distribution workflow. A Low rating identifies a documented non-dd-cfDNA rejection method rather than missing evidence for the assessed workflow. Interpretation Support is High for organ-specific reporting with clinical assistance and Medium for software or laboratory guidance. A Low rating identifies instrument-level output without documented organ-specific clinical interpretation support for transplant clinicians. Geographic Reach states verified operating areas without implying equal regulatory availability across every listed country.

Key Developments in the Multi-Organ Transplant AlloSure Monitoring Market

• In July 2025, CareDx announced the launch of AlloSure Plus and initial integration with EPIC Aura during the third quarter of 2025. The platform combines AlloSure dd-cfDNA with clinical variables to provide a personalized rejection risk assessment. CareDx stated that an international prospective study used more than 2,700 renal transplant biopsies for validation and the implementation requires center-level governance across ordering or interpretation and treatment escalation.
• In November 2025, Devyser Diagnostics enrolled the first patient in a prospective United States study of Devyser Accept cfDNA for kidney transplant monitoring. The planned study covers up to 400 recipients across six transplant centers and compares the assay with biopsy results. The program advances an FDA submission pathway for qualified transplant testing laboratories and commercial timing remains dependent on study completion or regulatory review plus adoption evidence from United States centers.
• In April 2026, Insight Molecular Diagnostics reported that a De Novo submission for the GraftAssure dd-cfDNA assay had been filed with the FDA on March 25 2026. The company positioned the assay as a local laboratory workflow supported by digital PCR technology. Regulatory review represents a material step toward decentralized commercial use but approval status must remain separate from current research and laboratory deployment claims across every customer evaluation.
• In June 2026, Verici Dx received New York State approval for the Tutivia kidney transplant rejection test and established nationwide United States access through its clinical laboratory. Tutivia uses a preclinical acute rejection transcriptomic signature rather than dd-cfDNA measurement within its kidney-focused clinical assessment. The approval expands commercial reach for an organ-specific alternative but adoption depends on clinician education and payer acceptance across programs with different surveillance protocols or laboratory relationships.

Key Players in the Multi-Organ Transplant AlloSure Monitoring Market

Multi-Organ Clinical Monitoring Providers

• CareDx
• Natera
• Thermo Fisher Scientific

Kidney-Focused Diagnostic Providers

• Eurofins Transplant Genomics
• Devyser Diagnostics
• Verici Dx

Decentralized and Enabling Platforms

• Insight Molecular Diagnostics
• Bio-Rad Laboratories

Multi-Organ Transplant AlloSure Monitoring Market - Report Scope

Coverage field	Report scope
Market breakdown	By Test Type, Organ Type, Application, End User, and region
Market Definition	Products and services used directly for molecular monitoring of graft injury or rejection across solid-organ transplant pathways.
Regions Covered	North America; Latin America; Western Europe; Eastern Europe; East Asia; South Asia and Pacific; Middle East and Africa
Countries Covered	USA; UK; Germany; Japan; South Korea
Key Companies Profiled	CareDx; Natera; Eurofins Transplant Genomics; Thermo Fisher Scientific; Devyser Diagnostics; Insight Molecular Diagnostics; Bio-Rad Laboratories; Verici Dx
Forecast Period	2026 to 2036
Approach	Hybrid bottom-up and top-down market sizing supported by official statistics and company records or regulatory evidence and defined commercial assumptions.

Multi-Organ Transplant AlloSure Monitoring Market - Research Methodology

Method	Approach
Primary Research	FMI analysts gathered input from manufacturers, service providers, technology developers, distributors, end users, procurement teams, and subject-matter experts. Interviews examined purchasing decisions, product or service evaluation, adoption barriers, approval requirements, pricing considerations, and expectations for technical or commercial support. Respondents were also asked what evidence is required before a trial, pilot, or initial order develops into regular purchasing.
Desk Research	Desk research covered government statistics, regulatory publications, trade data, industry associations, technical literature, standards, company filings, product information, and official corporate announcements. Sources were reviewed for relevance, publication date, geographic coverage, and consistency with the defined market scope. Claims relating to performance, applications, approvals, capacity, investment, and commercial activity were retained only when supported by credible public evidence.
Market Sizing and Forecasting	The market model combined the baseline value with historical performance, segment structure, pricing and volume indicators, adoption levels, company participation, and country-level demand conditions. Forecast assumptions considered economic activity, investment trends, regulatory developments, technology adoption, purchasing cycles, supply availability, and barriers to wider market use. Segment and regional estimates were reconciled before the final market total was calculated.
Data Validation	Estimates were checked against multiple independent indicators, including public data, company activity, trade patterns, industry developments, and findings from primary interviews. Validation also tested whether products, services, applications, and company revenues fell within the defined market boundaries. Adjacent categories, unsupported claims, overlapping revenues, and activities without direct market relevance were excluded to reduce double counting and maintain consistency across segments and countries.

Multi-Organ Transplant AlloSure Monitoring Market by Segments

Multi-Organ Transplant AlloSure Monitoring Market segmented by Test Type:

• Donor-derived Cell-free DNA (dd-cfDNA) Monitoring
• Combined Biomarker Testing
• Gene Expression Profiling
• Immune Monitoring Assays

Multi-Organ Transplant AlloSure Monitoring Market segmented by Organ Type:

• Kidney Transplantation
• Heart Transplantation
• Lung Transplantation
• Liver Transplantation

Multi-Organ Transplant AlloSure Monitoring Market segmented by Application:

• Acute Rejection Monitoring
• Routine Post-transplant Surveillance
• Immunosuppression Management
• Graft Dysfunction Assessment

Multi-Organ Transplant AlloSure Monitoring Market segmented by End User:

• Transplant Centers
• Hospitals
• Diagnostic Laboratories
• Specialty Clinics

Multi-Organ Transplant AlloSure Monitoring Market by Region:

• North America
  • United States
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
• Western Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Benelux
  • Nordics
• Eastern Europe
  • Poland
  • Czech Republic
  • Romania
  • Hungary
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia and New Zealand
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Türkiye
  • Israel

Research Sources and Bibliography

• Natera, Inc.. (2026, June 18).
• Centers for Medicare & Medicaid Services. (2026, July 16).
• CareDx, Inc.. (2026, June 18).
• United Network for Organ Sharing. (2026, January 28).
• Natera, Inc.. (2026, June 25).
• CareDx, Inc.. (n.d.).
• Health Resources and Services Administration. (2026, January).
• Centers for Medicare & Medicaid Services. (2026, July 8).
• CareDx, Inc.. (n.d.).
• Centers for Medicare & Medicaid Services. (2026, January 22).
• NHS Blood and Transplant. (2026, March 17).
• Deutsche Stiftung Organtransplantation. (2026, January 13).
• Japan Organ Transplant Network. (2026, June 30).
• Ministry of Health and Welfare, Republic of Korea. (2025, April 30).
• Bio-Rad Laboratories, Inc.. (2025, February 13).
• CareDx, Inc.. (2025, July 31).
• Devyser Diagnostics AB. (2025, November 25).
• Insight Molecular Diagnostics Inc.. (2026, April 14).
• Verici Dx plc. (2026, June 24).
• Eurofins Transplant Genomics. (n.d.).
• Thermo Fisher Scientific. (n.d.).
• Insight Molecular Diagnostics Inc.. (n.d.).
• Verici Dx plc. (n.d.).

The bibliography provides verified reader references and does not represent every source used throughout the complete commercial research program. The full report contains the complete source base used for market sizing and forecasting or company and country assessment.

This Report Answers

• How large is the multi-organ transplant AlloSure monitoring market in 2026 and 2036?
• Which clinical and operating conditions support demand for molecular transplant surveillance?
• Why does donor-derived cell-free DNA monitoring hold the leading Test Type share in 2026?
• How does kidney transplantation influence test volume and clinical pathway design?
• Why does acute rejection monitoring account for the leading Application share in 2026?
• How do country growth rates differ across the USA, UK, Germany, Japan, and South Korea?
• Which companies provide multi-organ services or organ-specific transplant monitoring workflows?
• What limits reimbursement and routine adoption across transplant centers and diagnostic laboratories?
• How can integrated reporting connect molecular evidence with biopsy and immunosuppression decisions?